user

CONDITIONAL RESOLUTIONS IN THE AMNOG EARLY BENEFIT ASSESSMENT

被引：0
|
作者：
Assmann, G. [1 ]
Schmidt, U. [1 ]
Drechsler, M. [1 ]
Pfannkuche, M. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1161
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP225
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [1] Early Benefit Assessment The first Month of AMNOG - an Analysis
    Riese, Anna
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2014, 19 (06): : 253 - 253
  • [2] RELEVANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT (AMNOG)
    Lebioda, A.
    Gasche, D.
    Dippel, F. W.
    Plantoer, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A484 - A485
  • [3] The Definition and Role of Quality of Life in the Context of the early Benefit Assessment by AMNOG
    Lohrberg, D.
    Augustin, M.
    Blome, C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 105 - 105
  • [4] AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY - A SPECIFIC CHALLENGE FOR ANTIDIABETICS
    Bless, H.
    Mathes, J.
    Kotowa, W.
    Luebker, C.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A680 - A681
  • [5] OVERVIEW OF GERMAN AMNOG DOSSIERS WITH PRICE ANALYSIS BEFORE AND AFTER EARLY BENEFIT ASSESSMENT
    Bonduelle, D.
    Batscheider, A.
    Tremmel, M.
    Antoni, B.
    Bocuk, D.
    Roxlau, T.
    Mihaylova, E.
    [J]. VALUE IN HEALTH, 2018, 21 : S190 - S190
  • [6] IMPACT OF TRIAL DESIGN ON PRICE DISCOUNTS AFTER EARLY BENEFIT ASSESSMENT (AMNOG) IN GERMANY
    Theidel, U.
    Lopmeier, J.
    Mittendorf, T.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A501 - A501
  • [7] AMNOG - SUMMARY OF OUTCOMES OF EARLY BENEFIT ASSESSMENT AND REIMBURSEMENT NEGOTIATION FOR NEW DRUGS IN GERMANY
    Claus, V
    Freyer, D.
    Kotowa, W.
    Mathes, J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A316 - A316
  • [8] HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME
    Reindl, S.
    Kotowa, W.
    Mathes, J.
    Hoeer, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S785 - S785
  • [9] HR-QOL DATA IN THE AMNOG EARLY BENEFIT ASSESSMENT: INDUSTRY AND IQWIG/GBA PERSPECTIVE
    Obradovic, M.
    Radicek, S.
    Rauland, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A422 - A423
  • [10] AMNOG BENEFIT ASSESSMENT IN GERMANY: OUTCOMES FROM 2011 TO 2022
    Paegelow, D.
    Fischer-Huchzermeyer, S.
    Loepmeier, J. F.
    Schwerbel, K.
    Kulp, W.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S332 - S332
12345